Globe Life: Discounted Protection Franchise with Steady Momentum

What happened

Globe Life continues to exhibit operational strength with premium growth (+5% in 2024), rising sales, and improving investment income, bolstered by underwriting discipline and AI initiatives. The company's capital return program remains robust, supported by an RBC ratio of 316% and a $1.8B buyback authorization, which together provide a strong floor for shareholder value. However, the stock trades at a discount (~9.5-10x TTM EPS) relative to protection peers, reflecting ongoing overhangs from sales practice controversies and potential NAIC RBC recalibration. While near-term headwinds persist, the core franchise—scaled captive/direct distribution and consistent cash generation—remains intact, and any normalization of legal/regulatory headlines could unlock multiple expansion. Given the cheap valuation and durable earnings stream, the risk/reward skews favorably for long-term investors who can look through the noise.

Implication

Globe Life offers a compelling opportunity for patient investors. The protection business delivers recurring cash flows and is undervalued relative to peers. Sustained buybacks and improving productivity (Liberty National, AI initiatives) should drive per-share value. Key catalysts include resolution of controversies and benign NAIC RBC changes. We maintain a BUY stance with a target price reflecting 11-12x normalized EPS.

Thesis delta

The Zacks article and latest filings reaffirm our BUY thesis. There is no material change in the investment case; operating momentum and capital returns continue to support the discounted valuation. The primary risk remains the resolution of legal and regulatory overhangs, but the core fundamentals have not deteriorated.